top of page

Carrier Screening

Updated: May 10

Carrier screening is done to determine whether an individual carries a genetic mutation for a specific disorder. While carriers themselves may not exhibit symptoms of the disorder, they have the potential to pass the mutated gene to their offspring. Carrier screening aims to identify individuals at risk of transmitting genetic disorders to their children, allowing for informed family planning decisions.

Key Aspects of Carrier Screening:

  1. Recessive Inheritance: Carrier screening is most commonly performed for conditions that follow an autosomal recessive inheritance pattern, where two copies of the mutated gene are required for the offspring to inherit the disorder.

  2. Common Disorders: Carrier screening panels typically target a range of common genetic disorders, including cystic fibrosis, sickle cell disease, Tay-Sachs disease, and thalassemia, among others.

  3. Population-Specific Screening: Some genetic disorders are more prevalent in certain ethnic or racial groups. Population-specific carrier screening helps to identify individuals at higher risk within these populations.

Prenatal Genetic Testing:

Prenatal genetic testing involves various diagnostic and screening tests performed during pregnancy to assess the health and genetic makeup of the fetus. These tests provide crucial information about the presence of genetic disorders, chromosomal abnormalities, and other developmental anomalies, allowing parents to make informed decisions about their pregnancy and prepare for potential medical needs.


Carrier screening and ultrasound done during pregnancy

Types of Prenatal Genetic Tests:

  1. Non-Invasive Prenatal Testing (NIPT): It starts with Blood Sample Collection requiring a simple blood draw from the mother, usually performed after 10 weeks of gestation, after taking informed consent. Isolation and Analysis of Fetal DNA: Specialized laboratory techniques are employed to isolate and analyze the cell-free fetal DNA present in the maternal blood sample. Screening for Chromosomal Abnormalities: NIPT primarily screens for common chromosomal abnormalities such as Down syndrome (trisomy 21), trisomy 18, and trisomy 13, as well as sex chromosome abnormalities like Turner syndrome (monosomy X) and Klinefelter syndrome (XXY). High Sensitivity and Specificity: NIPT has demonstrated high sensitivity and specificity for detecting chromosomal abnormalities, while NIPT is highly accurate, false positive and false negative results can still occur, necessitating confirmatory diagnostic testing such as amniocentesis or chorionic villus sampling (CVS).

  2. Amniocentesis: Amniocentesis is a diagnostic procedure used to obtain a sample of amniotic fluid surrounding the fetus in the uterus. This procedure allows for the direct analysis of fetal cells and genetic material, providing detailed information about chromosomal abnormalities, genetic disorders, and neural tube defects. The sample is collected by inserting a thin needle into the mother's abdominal wall and the amniotic sac under ultrasound guidance. A small amount of amniotic fluid is withdrawn for analysis. Amniocentesis is considered highly accurate for diagnosing chromosomal abnormalities and genetic disorders, with a low rate of false positive and false negative results. While amniocentesis is generally safe and is performed between 15-20 weeks of pregnancy, there is a small risk of complications such as miscarriage, infection, or injury to the fetus or placenta.

  3. Chorionic Villus Sampling (CVS): Chorionic Villus Sampling (CVS) is another diagnostic procedure used to collect fetal genetic material for analysis. Unlike amniocentesis, which collects amniotic fluid, CVS involves sampling tissue from the chorionic villi, small finger-like projections on the placenta that share the same genetic makeup as the fetus. A small sample of tissue is collected for analysis by inserting a thin tube or needle through the cervix or the abdominal wall to reach the chorionic villi on the placenta. Early Detection: CVS can be performed earlier in pregnancy compared to amniocentesis, typically between 10 and 13 weeks of gestation, providing earlier insights into fetal genetic health, however, like amniocentesis, CVS also carries a minor risk of miscarriage, infection, or injury to the fetus or placenta.

  4. Ultrasound Imaging: While not a genetic test per se, ultrasound imaging is commonly used during pregnancy to assess fetal development, detect structural abnormalities, and guide the timing and necessity of genetic testing procedures mentioned above. Ultrasound imaging allows for a detailed assessment of fetal anatomy, including the brain, spine, heart, limbs, and internal organs. Ultrasound measurements of fetal size and growth parameters help monitor fetal development and detect growth abnormalities. It can identify structural abnormalities such as cleft lip and palate, heart defects, and neural tube defects like spina bifida. Specialized ultrasound techniques, such as fetal echocardiography, focus on evaluating the structure and function of the fetal heart, aiding in the diagnosis of congenital heart defects.


-Written by Sohni Tagore

Comments


bottom of page